Lessons learned from a highly-active CD22-specific chimeric antigen receptor

OncoImmunology

Volumn 2, Issue 4, 2013, Pages

  Long, Adrienne H ^a   Haso, Waleed M ^a   Orentas, Rimas J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Adoptive immunotherapy; ALL; CD22; Leukemia; Retroviral vectors

Indexed keywords

ANTINEOPLASTIC AGENT; CD137 ANTIGEN; CD19 ANTIGEN; CD22 ANTIGEN; CD28 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; EPITOPE; IMMUNOGLOBULIN G1; IMMUNOTOXIN; IMMUNOTOXIN BL22; IMMUNOTOXIN HA22; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY M971; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOPTIVE TRANSFER; ARTICLE; BINDING AFFINITY; CANCER IMMUNOTHERAPY; CELL SPECIFICITY; DNA MODIFICATION; DRUG DESIGN; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG STRUCTURE; HUMAN; MOLECULARLY TARGETED THERAPY; NONHUMAN; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN TARGETING; TUMOR XENOGRAFT;

EID: 84886944148     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.23621     Document Type: Article

References (10)

1. Davila ML, Brentjens R, Wang X, Rivière I, Sadelain M. How do CARs work?: Early insights from recent clinical studies targeting CD19. Oncoimmunology 2012; 1:1577-83; PMID:23264903; http://dx.doi.org/10.4161/onci.22524
2. Haso W, Lee DW, Shah NN, Stetler-Stevenson M, Yuan CM, Pastan IH, et al. Anti-CD22-chimeric antigen receptors targeting B cell precursor acute lymphoblastic leukemia. Blood 2012; PMID:23243285; http://dx.doi.org/10.1182/blood-2012-06-438002
3. Wayne AS, Kreitman RJ, Findley HW, Lew G, Delbrook C, Steinberg SM, et al. Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial. Clin Cancer Res 2010; 16:1894-903; PMID:20215554; http://dx.doi.org/10.1158/1078-0432.CCR-09-2980
4. Mussai F, Campana D, Bhojwani D, Stetler-Stevenson M, Steinberg SM, Wayne AS, et al. Cytotoxicity of the anti-CD22 immunotoxin HA22 (CAT-8015) against paediatric acute lymphoblastic leukaemia. Br J Haematol 2010; 150:352-8; PMID:20528877; http://dx.doi.org/10.1111/j.1365-2141.2010.08251.x
5. James SE, Greenberg PD, Jensen MC, Lin Y, Wang J, Till BG, et al. Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane. J Immunol 2008; 180:7028-38; PMID:18453625
6. Xiao X, Ho M, Zhu Z, Pastan I, Dimitrov DS. Identification and characterization of fully human anti-CD22 monoclonal antibodies. MAbs 2009; 1:297-303; PMID:20065646; http://dx.doi.org/10.4161/mabs.1.3.8113
7. Bang SH, Nagata S, Onda M, Kreitman RJ, Pastan I. HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity. Clin Cancer Res 2005; 11:1545-50; PMID:15746059; http://dx.doi.org/10.1158/1078-0432.CCR-04-1939
8. Chmielewski M, Hombach A, Heuser C, Adams GP, Abken H. T cell activation by antibody-like immunoreceptors: increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity. J Immunol 2004; 173:7647-53; PMID:15585893
9. Guest RD, Hawkins RE, Kirillova N, Cheadle EJ, Arnold J, O'Neill A, et al. The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens. J Immunother 2005; 28:203-11; PMID:15838376; http://dx.doi.org/10.1097/01.cji.0000161397.96582.59
10. Kochenderfer JN, Yu Z, Frasheri D, Restifo NP, Rosenberg SA. Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood 2010; 116:3875-86; PMID:20631379; http://dx.doi.org/10.1182/blood-2010-01-265041